{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+acetate+plus+prednisone+%28AAP%29", "query": { "intervention": "Abiraterone acetate plus prednisone (AAP)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-06T10:46:54.251Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04662580", "title": "ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "ARX517", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 183, "start_date": "2021-05-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 12, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04662580" }, { "nct_id": "NCT05818683", "title": "A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Neoplasms", "Metastatic Hormone-sensitive Prostate Cancer" ], "interventions": [ { "name": "Pasritamig", "type": "DRUG" }, { "name": "Cetrelimab", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone acetate plus prednisone (AAP)", "type": "DRUG" }, { "name": "Lutetium Lu-177 vipivotide tetraxetan", "type": "DRUG" }, { "name": "JNJ-101556143", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 300, "start_date": "2023-04-26", "completion_date": "2028-05-23", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 7, "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • St Louis, Missouri + 4 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05818683" }, { "nct_id": "NCT02257736", "title": "An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aragon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 982, "start_date": "2014-11-26", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 46, "location_summary": "Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257736" }, { "nct_id": "NCT04947254", "title": "Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Carcinoma", "Stage IIC Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 200, "start_date": "2021-08-05", "completion_date": "2028-06-07", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04947254" }, { "nct_id": "NCT03748641", "title": "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Castration-Resistant Prostatic Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "New Formulation of Niraparib and Abiraterone Acetate (AA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 765, "start_date": "2019-01-25", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 47, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03748641" }, { "nct_id": "NCT04497844", "title": "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Niraparib+ Abiraterone acetate fixed dose combination (FDC)", "type": "COMBINATION_PRODUCT" }, { "name": "Abiraterone acetate (AA)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo FDC", "type": "DRUG" }, { "name": "Placebo AA", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 696, "start_date": "2020-09-23", "completion_date": "2027-11-01", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 53, "location_summary": "Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04497844" }, { "nct_id": "NCT02123758", "title": "A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms", "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "JNJ-56021927", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aragon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 57, "start_date": "2014-07-09", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 3, "location_summary": "Los Angeles, California • San Francisco, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02123758" }, { "nct_id": "NCT05295927", "title": "A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "EPI-7386", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone or Prednisolone", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-03-23", "completion_date": "2022-09-30", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 3, "location_summary": "Towson, Maryland • Omaha, Nebraska • Myrtle Beach, South Carolina", "locations": [ { "city": "Towson", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05295927" }, { "nct_id": "NCT04577833", "title": "A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Abiraterone Acetate (AA)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 136, "start_date": "2020-11-13", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-06T10:46:54.251Z", "location_count": 1, "location_summary": "West Valley City, Utah", "locations": [ { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04577833" } ] }